Login to Your Account



Shire Extends RegenMed Reach in $200M Pervasis Acquisition

By Marie Powers
Staff Writer

Wednesday, April 18, 2012
Shire plc pumped up its regenerative medicine business by acquiring all but the oncology assets of privately held Pervasis Therapeutics Inc., which is developing an endothelial cell-based technology, in a deal valued at up to $200 million.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription